Our team has taken the lead in coordinating a collaborative network involving 38 global centers. We conducted a systematic analysis of clinical, MICM (morphology, immunophenotype, cytogenetics, molecular biology), and transcriptome data, defining RARG-AML as a new subtype of leukemia for the first time. With various techniques such as cell lines containing RARG fusion genes, CDX/PDX mouse models, single-cell sequencing, CHIP-Seq, and RNA-Seq, we explored the interactions between pathogenic proteins and DNA with other proteins, elucidating the molecular mechanisms inRARG-AML. To identify effective therapeutic drugs, we employed c-MAP and a high-throughput drug screening platform. Ultimately, we established new standards for the diagnosis, risk assessment, and treatments of RARG-AML.

Unique gene expression profiles of RARG-AML

Elderly patients (≥60 years old) represent a substantial proportion of AML patients. Due to organ aging and declining functions in the elderly, they often cannot tolerate intensive therapy and transplantation, resulting in a 2-year survival rate of 38%. This situation provides valuable direction and insight for the treatment of elderly AML. In elderly AML patients, targeted therapeutics can not only eliminate leukemia cells but also activate the immune cells to enhance the killing and surveillance functions of the immune system, aiming to improve the overall quality of life for AML patients.

1. Established a complete oral, chemo-free and outpatient regimen for APL patients(J Clin Oncol, 2013; N Eng J Med, 2014b; Lancet Oncol, 2018; Blood, 2018, 2019; J Hematol Oncol, 2022)

3. Established Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia.

Eastablished homoharringtonine,  aclarubicin and cytarabine (HAA) regimen and MRD-Directed Risk-Stratification Treatment in t (8; 21) AML(Lancet Haemtol, 2022; Am J Hematol, 2020; Blood Caner J, 2018; Blood, 2013; Leuk Res, 2013; Leuk Res, 2015; Cancer Med,2016)